# Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

> **NCT04547777** · PHASE1 · RECRUITING · sponsor: **Darell Bigner** · enrollment: 90 (estimated)

## Conditions studied

- Glioma, Malignant

## Interventions

- **DRUG:** D2C7-IT
- **DRUG:** 2141-V11

## Key facts

- **NCT ID:** NCT04547777
- **Lead sponsor:** Darell Bigner
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-09
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04547777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04547777, "Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04547777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*